Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers

By Svane Inge   Pedersen Anders   Johansen Julia   Johnsen Hans   Nielsen Dorte   Kamby Claus   Ottesen Svend   Balslev Eva   Gaarsdal Eva   Nikolajsen Kirsten   Claesson Mogens  

Cancer Immunology, Immunotherapy, Vol. 56, Iss. 9, 2007-09 ,pp. : 1485-1499

Springer Publishing Company

Access to resources Recommend Favorite

Phase I clinical study of a personalized peptide vaccination available for six different human leukocyte antigen (HLA-A2, -A3, -A11, -A24, -A31 and -A33)-positive patients with advanced cancer

By                    

Experimental and Therapeutic Medicine, Vol. 2, Iss. 1, 2011-01 ,pp. : 109-117

Spandidos Publications

Access to resources Recommend Favorite

A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients

By                      

Oncology Reports, Vol. 30, Iss. 3, 2013-01 ,pp. : 1094-1100

Spandidos Publications

Access to resources Recommend Favorite

Co-transfection of dendritic cells with AFP and IL-2 genes enhances the induction of tumor antigen-specific antitumor immunity

By          

Experimental and Therapeutic Medicine, Vol. 4, Iss. 4, 2012-01 ,pp. : 655-660

Spandidos Publications

Access to resources Recommend Favorite

Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination

By Romero Pedro   Cerottini Jean-Charles   Speiser Daniel  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 3, 2004-03 ,pp. : 249-255

Springer Publishing Company

Access to resources Recommend Favorite